<DOC>
	<DOCNO>NCT02868892</DOCNO>
	<brief_summary>Patients advance recurrent adenocarcinoma adenosquamous cell carcinoma cervix receive Pemetrexed .</brief_summary>
	<brief_title>A Study Pemetrexed Recurrent Cervical Adenocarcinomas</brief_title>
	<detailed_description>Patients receive Pemetrexed 500 mg/m2 every three week . On initiation pemetrexed , day one first chemotherapy cycle , patient begin take folic acid dose 350 600 mcg daily well receive intramuscular injection 1000 mcg vitamin B12 , subsequent vitamin B12 injection give every 9 week study .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Adenosquamous</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Patients must advance recurrent adenocarcinoma adenosquamous cell carcinoma cervix document disease progression 2 . Patients must measurable disease define least one lesion could accurately measure least one dimension , must 20 mm measure conventional technique include palpation , plain Xray , computerize tomography ( CT ) , magnetic resonance imaging ( MRI ) 10 mm measure spiral CT 3 . 18 year age old 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status score &lt; 2 life expectancy &gt; 3 month 5 . Life expectancy ≥ 12 week 6 . Participants must measureable disease RECIST criteria 7 . Absolute neutrophil count &gt; 1500 mm3 , platelet count ≥ 100×109 L , hemoglobin ≥ 8.5 g/dL 8 . Creatinine clearance ≥ 45 mL/min use standard Cockcroft Gault formula ( ) glomerular filtration rate ( GFR ) measure Tc99mdiethylenetriaminepentacetate ( DPTA ) serum clearance method : 1 . Males : [ 140 Age year ] × Actual Body Weight ( kg ) 72 × Serum Creatinine ( mg/dL ) 2 . Females : Estimated creatinine clearance male × 0.85 9 . Total bilirubin ≤ 2 mg/dL , aspartate transaminase ( AST ) alanine transaminase ( ALT ) AST/ALT ≤ 5 time upper limit normal range 10 . At least 21 day administration chemotherapy 11 . No remain grade 2 high toxicity prior cancer therapy unless judge clinically insignificant Principal Investigator 12 . At least four ( 4 ) week prior major surgery 13 . Willingness provide permission access archive tumor sample additional blood sample evaluation Foundation One Analysis available Enterprise wide . 14 . Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must willing use acceptable contraceptive method ( abstinence , oral contraceptive double barrier method ) duration study 30 day follow last dose study drug , must negative urine serum pregnancy test within 2 week prior begin treatment trial . 1 . Uncontrolled cardiac disease , congestive heart failure , angina , arrhythmias hypertension . 2 . Myocardial infarction unstable angina within 2 month treatment . 3 . Known human immunodeficiency virus ( HIV ) infection chronic active Hepatitis B C ( patient NOT require test presence virus prior therapy protocol ) . 4 . Active clinically serious infection &gt; CTCAE ( version 4.03 ) Grade 2 . 5 . Thrombotic embolic event cerebrovascular accident include transient ischemic attack within past 6 month . 6 . Pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 week first dose study drug . 7 . Any hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 week first dose study drug . 8 . Serious nonhealing wound , ulcer , bone fracture . 9 . Major surgery , open biopsy significant traumatic injury within 4 week first study drug . 10 . Inability complete inform consent process adhere protocol treatment plan followup requirement . 11 . Concurrent severe illness active infection , psychiatric illness/social situation would limit safety compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>